AstraZeneca Financial Statements
AstraZeneca Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
AstraZeneca Income Statement
| 2007+ | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | -- | 29,559.0 | 26,460.8 |
| Gross Profit ($ mil.) | -- | 22,892.0 | -- |
| Operating Income ($ mil.) | -- | 8,094.0 | -- |
| Total Net Income ($ mil.) | -- | 5,627.0 | -- |
| Diluted EPS (Net Income) | -- | -- | -- |
- # Fiscal year-end changed since last report from December to December
AstraZeneca Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 0.23 | 3.75 | 1.56 |
| Price/Earnings Ratio | -- | 16.34 | 15.82 |
| Price/Book Ratio | 0.46 | 2.92 | 1.52 |
| Price/Cash Flow Ratio | 0.91 | 13.17 | 9.88 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed AstraZeneca Financial Ratios
AstraZeneca Competitive Intelligence
| GlaxoSmithKline | Merck | Novartis | |
|---|---|---|---|
| Annual Sales ($ mil.) | 22,716.0 | 24,197.7 | 38,947.0 |
| Employees | 103,401 | 59,800 | 98,200 |
| Market Cap ($ mil.) | -- | 77,471.9 | -- |
Competitive Landscape
